Semaglutide and mood

Semaglutide, the drug behind Ozempic and Wegovy, is drawing new attention for something beyond weight and blood sugar: lower rates of depression, anxiety, and some addiction harms in recent analyses. (bmj.com, jamanetwork.com) Semaglutide belongs to a class called glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, which mimic a gut hormone that helps control appetite and blood glucose. Researchers are also studying whether those drugs affect brain circuits tied to reward, craving, and impulse control. (bmj.com, nature.com) The biggest new signal came in a BMJ cohort study published March 4, 2026, using Veterans Affairs records from 606,434 US veterans with type 2 diabetes. It compared people starting a GLP-1 drug with people starting a sodium-glucose cotransporter-2 inhibitor, another diabetes medicine, and followed them for up to three years. (bmj.com) In veterans without a prior substance use disorder, GLP-1 starters had lower risks of new alcohol, cannabis, cocaine, nicotine, opioid, and other substance use disorders. The hazard ratio was 0.86 for the combined outcome, with individual estimates ranging from 0.75 for opioid-related disorders to 0.87 for other substances. (bmj.com) In veterans who already had a substance use disorder, the same study linked GLP-1 use to fewer substance-related emergency visits, hospital admissions, and deaths, plus fewer overdoses and suicidal behavior. A linked BMJ opinion piece said the difference worked out to about 12 fewer serious events and two fewer deaths per 1,000 users over three years. (bmj.com, bmj.com) The mood story did not start with the veterans study. A JAMA Psychiatry systematic review and meta-analysis published online May 14, 2025, pooled more than 107,000 patients from clinical trials and found GLP-1 drugs were not associated with increased psychiatric adverse events, while mental health-related quality-of-life scores improved. (jamanetwork.com) A separate JAMA Internal Medicine analysis published in 2024 looked at 52,783 people taking semaglutide for weight management and reported lower risks of suicidal ideation in the first six months than with non-GLP-1 anti-obesity drugs. The same paper reported similar patterns for incident anxiety and depression. (jamanetwork.com) Addiction-specific semaglutide data also appeared before the veterans paper. A Nature Communications study published May 28, 2024, analyzed 83,825 patients with obesity and found semaglutide was associated with a 50% to 56% lower risk of incident and recurrent alcohol use disorder over 12 months, with similar findings in a separate cohort of 598,803 people with type 2 diabetes. (nature.com) The caution is that these are mostly observational studies, which can show patterns without proving that semaglutide caused them. That matters because people who start GLP-1 drugs can differ from comparison patients in ways that databases do not fully capture, even after statistical adjustment. (bmj.com, nature.com) Regulators and researchers have also been tracking possible psychiatric side effects, not just benefits. A 2024 JAMA Network Open disproportionality analysis of World Health Organization safety reports identified signals involving suicidal ideation with semaglutide and liraglutide, which is one reason newer trial and real-world analyses have drawn close scrutiny. (jamanetwork.com) What happens next is more straightforward than the headlines: randomized trials have to test whether semaglutide really changes mood, craving, or addiction outcomes. For now, the strongest reading is that the drug’s mental-health profile looks more complicated — and possibly broader — than a weight-loss label suggests. (bmj.com, nature.com)